首页> 外文会议>2010 4th International Conference on Bioinformatics and Biomedical Engineering >Intragastric Administration of Lactobacillus casei Expressing Bovine Rotavirus VP7 Protein Induced Specific Antibody Production
【24h】

Intragastric Administration of Lactobacillus casei Expressing Bovine Rotavirus VP7 Protein Induced Specific Antibody Production

机译:表达牛轮状病毒VP7蛋白的干酪乳杆菌的胃内给药诱导特异性抗体产生

获取原文

摘要

Abstract-The aim of this study is to explore the mucosal and systemic antibody immune responses induced by recombinant L.casei expressing the major immunoprotective antigen VP7 of bovine rotavirus (BRV). Two inducible expression vectors containing the antigenic dominant region of VP7 gene, pPG-1-VP7 (cell-surface expression vector) and pPG-2-VP7 (secretory vector), were constructed and electrotransformed into L. casei 393 to obtain positive recombinant bacteria designated rLc::pPG-1-VP7 or rLc::pPG-2-VP7. The expressions of VP7 protein induced by 2% lactose in MRS media were confirmed by western blot and indirect immunofluorescent staining using anti-VP7 antibody. Oral immunization of mice with the recombinant strains significantly increased anti-VP7 sIgA level in mouse vaginal lavages and feces samples, and anti-VP7 IgG level in serum compared with empty plasmid transformed bacteria. Results of neutralization assay clearly indicated that serum antibodies induced by oral vaccination have neutralization activity against BRV in vitro. The neutralizing titers are 1:62.9 and 1:50.6 for rLc::pPG-1-VP7 and rLc::pPG-2-VP7, respectively. Our results demonstrated that Lactobacillus casei expressing rBRV-VP7 have application potentials in producing oral vaccine against BRV. (Abstract)
机译:摘要-本研究的目的是探讨表达牛轮状病毒(BRV)主要免疫保护抗原VP7的重组干酪乳杆菌诱导的粘膜和全身抗体免疫反应。构建了两个含有VP7基因抗原性显性区的诱导型表达载体pPG-1-VP7(细胞表面表达载体)和pPG-2-VP7(分泌型载体),并将其电转化入干酪乳杆菌393以获得阳性重组细菌。指定为rLc :: pPG-1-VP7或rLc :: pPG-2-VP7。 Western blot和抗VP7抗体间接免疫荧光染色证实了2%乳糖诱导的MRS培养基中VP7蛋白的表达。与空质粒转化的细菌相比,重组菌株的小鼠口服免疫显着提高了小鼠阴道灌洗液和粪便样品中的抗VP7 sIgA水平,以及血清中的抗VP7 IgG水平。中和测定的结果清楚地表明,口服疫苗诱导的血清抗体在体外具有抗BRV的中和活性。 rLc :: pPG-1-VP7和rLc :: pPG-2-VP7的中和效价分别为1:62.9和1:50.6。我们的结果表明,表达rBRV-VP7的干酪乳杆菌在生产抗BRV的口服疫苗方面具有应用潜力。 (抽象的)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号